Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apollo And ReShape Swap Bariatric Devices

Executive Summary

Apollo Endosurgery sold its surgical product line, including the Lap-Band adjustable gastric banding system and other accessories for laparoscopic bariatric surgery, to ReShape Lifesciences for $17m plus other considerations, including the ReShape endoscopic balloon, the companies announced Dec. 18. The deal will allow Apollo to focus on endo-bariatric procedures while it gives ReShape an instant revenue stream and another product to sell to surgeons, its core customers.

You may also be interested in...



Gastric Balloon Labeling Updated After Patient Deaths

US FDA has approved updated labeling for Orbera Intragastric Balloon System and the ReShape Integrated Dual Balloon System in the wake of five more patient deaths.

EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon

The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.

Allergan trims off fat-busting portfolio to Apollo

Allergan has found a buyer for its underperforming obesity device business, nearly a year after putting it on the block. Austin, Texas-based Apollo EndoSurgery has definitively agreed to acquire the division, responsible for manufacturing and selling Allergan’s Lap-Band adjustable gastric band system and the Orbera intragastric balloon system, for up to $110m. The final consideration comprises a $75m upfront cash payment, a $15m stake in Allergan, and up to $20m in milestone payments linked to regulatory and sales targets.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT124400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel